^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    paclitaxel

    i
    Other names: BMY 45622, BMS-181339, NSC-125973, QW-8184, MBT-0206, NK-105, DHP-107
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    16h
    A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (clinicaltrials.gov)
    P1, N=328, Recruiting, HC Biopharma Inc.
    New P1 trial
    |
    EGFR mutation
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • etoposide IV
    24h
    ZSTK3744, a novel aryl hydrocarbon receptor agonist, exhibits efficacy against chemotherapy-resistant triple-negative breast cancer. (PubMed, Cancer Res Commun)
    Compared with parental cells, these resistant cells exhibited reduced sensitivity to paclitaxel, adriamycin, and eribulin in the viability assays. These results suggest that ZSTK3744 combines robust cell growth-inhibitory activity with a favorable safety profile. In conclusion, ZSTK3744 is a promising candidate for overcoming chemotherapy resistance in TNBC, addressing the urgent need for more effective treatment options for this aggressive cancer subtype.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • TIPARP (TCDD Inducible Poly(ADP-Ribose) Polymerase)
    |
    paclitaxel • doxorubicin hydrochloride • Halaven (eribulin mesylate)
    24h
    Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial. (PubMed, EClinicalMedicine)
    Patients received radiotherapy (50.4 Gy/28 in fractions on 5 days per week), concurrent chemotherapy (paclitaxel 135 mg/m2 d1+ cisplatin 25 mg/m2 d1-3, q3w, 2 cycles), and QL1706 (5 mg/kg q3w for up to 1 year [total of 18 cycles]). QL1706 combined with chemoradiotherapy demonstrated potential antitumor activity and manageable toxicity, supporting further investigation. National Natural Science Foundation of China, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Medical Discipline Construction Project, and Tianjin Key Medical Discipline (Specialty) Construction Project.
    P2 data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • FASLG (Fas ligand) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    TMB-H
    |
    cisplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    1d
    Ezrin (EZR) promotes breast cancer progression and drug resistance: Molecular mechanisms involving STAT3 activation and TPM3 interaction. (PubMed, Life Sci)
    EZR links cytoskeletal remodeling to STAT3 signalling to drive metastatic competence and paclitaxel resistance, nominating EZR as a potential therapeutic vulnerability in treatment-refractory breast cancer.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • TPM3 (Tropomyosin 3) • EZR (Ezrin)
    |
    paclitaxel
    2d
    Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov)
    P3, N=255, Recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2026 --> Jan 2026
    Trial initiation date • pMMR
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    2d
    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=168, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)
    2d
    NRG-GI007: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, NRG Oncology | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    carboplatin • paclitaxel • Telomelysin (suratadenoturev)
    2d
    IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=540, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    New P3 trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • IBI-354
    2d
    Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    MammaPrint®
    |
    paclitaxel • doxorubicin hydrochloride • Irene (pyrotinib) • cyclophosphamide • epirubicin
    3d
    Hypoxia Alleviation-Potentiated Chemotherapy Enhances Anti-PD-L1 Treatment for Triple-Negative Breast Cancer via Improving Tumor Immunogenicity and Inhibiting STAT3 Activation. (PubMed, ACS Appl Mater Interfaces)
    The combination of anti-PD-L1 and paclitaxel (PTX) is a standard-of-care regimen for triple-negative breast cancer (TNBC)...This project aims to construct an albumin-based nanomedicine coloaded with atovaquone (ATO) and PTX for targeted tumor delivery, thereby enhancing the therapeutic efficacy of ICBs...This transformative approach significantly enhances the therapeutic efficacy of combination chemotherapy, leading to potent suppression of primary tumors while concurrently preventing postoperative recurrence and pulmonary metastases. This project has the potential to introduce innovative strategies and methodologies aimed at overcoming the limited efficacy of PTX combined with ICBs in the treatment of TNBC.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    paclitaxel • atovaquone
    3d
    A Safety and Pharmacokinetic Study of Intraoperative Low-Intensity Focused Ultrasound–Mediated Blood–Brain Barrier Opening to Enhance the Therapeutic Efficacy of Paclitaxel in Patients with Glioblastoma (ChiCTR2600117632)
    P=N/A, N=5, Not yet recruiting, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    IDH wild-type
    |
    paclitaxel
    3d
    Chemotherapy plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer: An Exploratory Phase I Trial (ChiCTR2600116912)
    P=N/A, N=22, Not yet recruiting, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New trial
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • pitavastatin